Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ADCT, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Loncastuximab Tesirine (ADCT-402) FDA approved Apr 2021 · Zynlonta |
B-cell Non Hodgkin Lymphoma | Phase 2/3 · NCT05991388 | Recruiting |
| Odronextamab | B-cell Non Hodgkin Lymphoma | Phase 2/3 · NCT05991388 | Recruiting |
| Chimeric Antigen Receptor T-cells | B-cell Non Hodgkin Lymphoma | Phase 2/3 · NCT05991388 | Recruiting |
| Loncastuximab tesirine 75µg/Kg | Marginal Zone Lymphoma | Phase 2 · NCT05296070 | Recruiting |
| Camidanlumab Tesirine (ADCT-301) | Acute Myeloid Leukemia (AML) | Phase 2 · NCT04639024 | Terminated |
| Imvotamab | Non-Hodgkin Lymphoma | Phase 1/2 · NCT04082936 | Terminated |
| Loncastuximab tesirine 150 µg/Kg | Marginal Zone Lymphoma | Phase 2 · NCT05296070 | Recruiting |
| Idelalisib | Relapsed Follicular Lymphoma | Phase 2 · NCT04699461 | Terminated |
| Vincristine | Double-Expressor Lymphoma | Phase 2 · NCT05600686 | Suspended |
| Doxorubicin | Double-Expressor Lymphoma | Phase 2 · NCT05600686 | Suspended |
| Epratuzumab-cys-tesirine (ADCT-602) | Blasts 5 Percent or More of Bone Marrow Nucleated Cells | Phase 1/2 · NCT03698552 | Terminated |
| Melphalan | Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 · NCT05228249 | Withdrawn |
| Trastuzumab/Tesirine Antibody-drug Conjugate… | Breast Cancer | Phase 1 · NCT03125200 | Terminated |
| Mipasetamab Uzoptirine (ADCT-601) | Advanced Solid Tumors | Phase 1 · NCT05389462 | Terminated |
| Olintatug Tesirine (ADCT-901) | Advanced Solid Tumors | Phase 1 · NCT04972981 | Completed |
Also used in these trials (approved or third-party drugs, not ADCT's own candidates): Gemcitabine Hydrochloride, Rituximab, Etoposide Phosphate, Oxaliplatin, Carboplatin, Etoposide, Ifosfamide, Dexamethasone, Prednisone, Epcoritamab, Cyclophosphamide, Ibrutinib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ADCT holds $189.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $19.8M/quarter from operations, an estimated runway of 28.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 7 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ADCT files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Redmile Group, LLC 10% owner · +6.49M options |
Insider | 22,932,028 | 17.96% | 2026-03-31 |
| Bain Capital Life Sciences Opportunities | 5%+ holder (13G) | 14,825,625 | 11.61% | 2026-10-22 |
| Nantahala Capital Management, LLC | Institution (13G, 5%+) | 12,326,184 | 9.65% | 2026-06-30 |
| TCG Crossover GP II, LLC | 5%+ holder (13G) | 11,390,175 | 8.92% | 2025-10-27 |
| TCG Crossover Management, LLC | Institution (13F) | 11,390,175 | 8.92% | 2026-09-30 |
| Hans Peter Wild 10% owner |
Insider | 9,788,944 | 7.67% | 2025-05-15 |
| BlackRock, Inc. | Institution (13G, 5%+) | 6,857,815 | 5.37% | 2026-06-30 |
| AIGH Capital Management LLC | Institution (13F) | 4,324,327 | 3.39% | 2026-09-30 |
| Opaleye Management Inc. | Institution (13F) | 4,070,819 | 3.19% | 2026-09-30 |
| Goldman Sachs Group Inc | Institution (13F) | 3,485,435 | 2.73% | 2026-09-30 |
| Morgan Stanley | Institution (13F) | 2,717,262 | 2.13% | 2026-09-30 |
| Citadel Advisors Llc | Institution (13F) | 2,446,868 | 1.92% | 2026-09-30 |
Share count 127,667,695 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-06-30 filed 2026-07-02 |
MALLIK AMEET |
Award (A) | 675,000 | – | 2,121,769 |
| 2026-06-30 filed 2026-07-02 |
Zaki Mohamed |
Award (A) | 213,900 | – | 896,317 |
| 2026-06-30 filed 2026-07-02 |
GRAHAM PETER J |
Award (A) | 221,100 | – | 841,640 |
| 2026-06-30 filed 2026-07-02 |
Carmona Jose |
Award (A) | 203,700 | – | 938,076 |
| 2026-06-03 filed 2026-06-03 |
Monges Viviane |
Tax withholding (F) | 2,596 | $3.08 | 186,447 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ADCT and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →